Literature DB >> 20574137

Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease.

Yoshimitsu Soga1, Hiroyoshi Yokoi, Tomoko Urakawa, Atsushi Tosaka, Masashi Iwabuchi, Masakiyo Nobuyoshi.   

Abstract

BACKGROUND: The natural history of patients with intermittent claudication (IC) has been reported, but little is known about that of claudicant patients after endovascular therapy (EVT). METHODS AND
RESULTS: A total of 271 consecutive patients (mean age, 68+/-6 years, 82% men) with IC were treated with EVT for a de novo iliofemoral lesion. Primary patency was defined as treated vessel without re-stenosis and repeat revascularization. Major adverse cardiovascular event (MACE) included death, myocardial infarction and stroke. Median follow-up interval was 11.7+/-2.9 years. During the follow-up period, 132 patients died (cardiovascular death; 66%). Major amputation was performed in 4 patients. Primary patency rate was 82%, 79%, and 78% at 5, 10 and 15 years, respectively. Freedom from all-cause death (MACE) was 73% (69%), 58% (49%), and 43% (34%) at 5, 10 and 15 years. On multivariate Cox regression, Trans-Atlantic Inter-society Consensus grade C/D, and involvement of femoropopliteal lesion were independent predictors of primary patency. Independent predictors for overall survival were age, left ventricular dysfunction (ejection fraction <40%), coronary artery disease, diabetes, chronic kidney disease and below-the-knee disease.
CONCLUSIONS: Regardless of good clinical patency of treated vessel in patients with IC, survival was poor. Independent predictors were different between long-term patency and late mortality.

Entities:  

Mesh:

Year:  2010        PMID: 20574137     DOI: 10.1253/circj.cj-10-0077

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  4 in total

1.  Neointimal hyperplasia after stent placement across size-discrepant vessels in an animal study.

Authors:  Hisayuki Cho; Mineyoshi Nango; Yukimasa Sakai; Etsuji Sohgawa; Ken Kageyama; Shinichi Hamamoto; Toshiaki Kitayama; Akira Yamamoto; Yukio Miki
Journal:  Jpn J Radiol       Date:  2014-04-09       Impact factor: 2.374

2.  Outcomes of endovascular treatment of patients with intermittent claudication due to femoropopliteal disease.

Authors:  Ahmed A Naiem; Robert James Doonan; Oren K Steinmetz; Kent S MacKenzie; Elie Girsowicz; Jason P Bayne; Daniel I Obrand; Heather L Gill
Journal:  Vascular       Date:  2021-08-16       Impact factor: 1.105

3.  Two-year Clinical Outcomes Post Implantation of EpicTM Self-Expanding Nitinol Stents for the Aortoiliac Occlusive Disease in Patients with Peripheral Arterial Disease.

Authors:  Takuya Tsujimura; Osamu Iida; Masashi Fujita; Masaharu Masuda; Shin Okamoto; Takayuki Ishihara; Kiyonori Nanto; Takashi Kanda; Shota Okuno; Yasuhiro Matsuda; Masahiko Fujihara; Yoshiaki Yokoi; Toshiaki Mano
Journal:  J Atheroscler Thromb       Date:  2017-10-05       Impact factor: 4.928

4.  Eight-year outcome after invasive treatment of infrainguinal intermittent claudication: A population-based analysis from the Swedish vascular register (Swedvasc).

Authors:  Thordur Gunnarsson; Anders Gottsäter; Stefan Bergman; Thomas Troëng; Hans Lindgren
Journal:  SAGE Open Med       Date:  2020-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.